Abstract
Multiple myeloma (MM) is a haematopoietic malignancy of terminal differentiated clonal plasma cells. The clinical symptoms are caused by diffuse or multilocular infiltration of the bone marrow with osteolysis and suppression of the normal haematopoesis, as well as by the production of monoclonal immunoglobulins or fragments (light chains or heavy chains). The incidence is approximately 3–4/100 000/year. MM is a disease of the elderly. Approximately 15% of patients are aged 60 years or younger and a further 15% between 60 and 65 years. Fewer than 2% of the patients are younger than 40 years at diagnosis. This age distribution has implications for the population eligible for specific types of treatment, such as high-dose therapy and stem cell transplantation.

This publication has 62 references indexed in Scilit: